REUTERS - Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine.
- Teva to Buy Allergan Plc's Generic Drugs Unit for $40.5 Billion
- Teva Pharmaceutical Profit Beats Forecast, Raises 2015 Earnings Estimate
- FDA Okays First Generic Version of Teva's MS Drug Copaxone
The drug, sold under the brand name Bendeka, is approved for treating cancer patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.
Teva, which has licensed the drug from Eagle Pharmaceuticals Inc, is responsible for all U.S. commercial activities for Bendeka.